Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Aug 16, 2024

BUY
$0.41 - $0.86 $2,596 - $5,447
6,334 New
6,334 $5,000
Q1 2023

May 15, 2023

SELL
$0.9 - $1.34 $4 - $6
-5 Reduced 0.08%
6,334 $6,000
Q4 2022

Feb 14, 2023

BUY
$0.85 - $16.65 $277 - $5,444
327 Added 5.44%
6,339 $6,000
Q3 2022

Nov 14, 2022

BUY
$1.15 - $17.4 $13 - $208
12 Added 0.2%
6,012 $6,000
Q2 2022

Oct 27, 2022

SELL
$1.19 - $2.0 $29 - $50
-25 Reduced 0.41%
6,000 $9,000
Q2 2022

Aug 15, 2022

SELL
$1.19 - $2.0 $29 - $50
-25 Reduced 0.41%
6,000 $9,000
Q1 2022

Oct 27, 2022

BUY
$1.23 - $1.9 $30 - $47
25 Added 0.42%
6,025 $11,000
Q1 2022

May 13, 2022

BUY
$1.23 - $1.9 $29 - $45
24 Added 0.4%
6,025 $11,000
Q4 2021

Feb 14, 2022

BUY
$1.64 - $2.83 $1 - $2
1 Added 0.02%
6,001 $11,000
Q3 2021

Nov 15, 2021

BUY
$2.7 - $3.59 $16,200 - $21,540
6,000 New
6,000 $18,000

Others Institutions Holding MBRX

About Moleculin Biotech, Inc.


  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $73.2M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.